Network origin in Hugh Crawford first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Gamma Vaccines Pty Ltd.
 Gamma Vaccines Pty Ltd. BiotechnologyHealth Technology Gamma Vaccines Pty Ltd. develops broad-spectrum vaccines against influenza and bacterial pneumonia. The firm is also seeking opportunities to exploit its technology platform for veterinary applications, including the production of novel avian influenza vaccines for preventing bird flu outbreaks in poultry. The company was founded by Tim Hirst, Mohammed Alsharif and Jean Petre in July 2009 and is headquartered in Manuka, Australia.
3
| Private Company | Biotechnology | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Hugh Crawford via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Savine Therapeutics Pty Ltd.
 Savine Therapeutics Pty Ltd. Pharmaceuticals: GenericHealth Technology Savine Therapeutics Pty Ltd. develops vaccines for infectious diseases. The company was founded by Scott Anthony Thomson and Ian Alistair Ramshaw and is headquartered in Canberra, Australia. | Pharmaceuticals: Generic | Director/Board Member | |
| The University of Sydney | College/University | Corporate Officer/Principal | |
| University of Bristol | College/University | Corporate Officer/Principal | |
ANU Connect Ventures Pty Ltd.
 ANU Connect Ventures Pty Ltd. Investment ManagersFinance ANU Connect Ventures Pty Ltd (ANU Connect Ventures) is a venture capital subsidiary of Australian National University founded in 2005. The firm is headquartered in Canberra, Australia. | Investment Managers | President | |
Dosimetry & Imaging Pty Ltd.
 Dosimetry & Imaging Pty Ltd. Medical SpecialtiesHealth Technology Dosimetry & Imaging Pty Ltd. develops X-ray storage phosphor for use in radiation detection and medical imaging. The firm specializes in detecting radiation exposure for use in personal dosimetry, homeland security and medical therapeutic products and measures life time exposure and reduces an individual’s exposure. The company was founded by Hans Riesen in 2007 and is headquartered in Sydney, Australia. | Medical Specialties | Director/Board Member | |
| University of Kentucky | College/University | Undergraduate Degree | |
| The University of York | College/University | Graduate Degree | |
GPN Vaccines Ltd.
 GPN Vaccines Ltd. BiotechnologyHealth Technology GPN Vaccines Ltd. is an Australian biotechnology company that is developing a vaccine called Gamma-PN™ to protect against all strains of Streptococcus pneumoniae, which causes life-threatening pneumonia, bacteremia, meningitis, and middle ear infections. The company is based in Adelaide, Australia, and Tim Hirst has been the CEO since 2017. This disease is responsible for causing 1-2 million deaths worldwide each year, particularly in children. | Biotechnology | Chief Executive Officer |
Statistics
International
| Australia | 9 |
| United Kingdom | 3 |
| United States | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 5 |
| Electronic Technology | 2 |
| Finance | 2 |
| Technology Services | 2 |
Operational
| Director/Board Member | 6 |
| Chairman | 3 |
| Corporate Officer/Principal | 2 |
| Founder | 2 |
| Private Equity Investor | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Tim Hirst | 12 |
| Mohammed Alsharifi | 1 |
| Alan Irving | 1 |
- Stock Market
- Insiders
- Hugh Crawford
- Company connections
